Pulse Biosciences shifts focus to cardiac/oncology, cuts workforce 40%, gets $65M loan from chairman

PULSE BIOSCIENCES, INC.

Reduce workforce by ~40% (to 66 employees); $200K severance charges in Q3 2022.
Kevin Danahy named CEO (was CCO); Darrin Uecker becomes CTO; Robert Duggan appointed Executive Chairman.
Robert Duggan provides $65M unsecured loan at 5% interest, due March 20, 2024.
Company evaluating dermatology partnerships; plans investor day within 60 days.
Shift from dermatology to cardiovascular, oncology, and other healthcare verticals.

item 1.01 item 2.03 item 2.05 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Robert Duggan

Executive Chairman

PLSE · PULSE BIOSCIENCES, INC.

Effective: 2022-09-20
Filed: September 23, 2022, 7:59 PM ET

Effective September 20, 2022, Mr. Duggan, who currently serves as a director and chairman of the Company’s Board, was elected Executive Chairman of the Board.

Role change

Kevin Danahy

Chief Executive Officer

PLSE · PULSE BIOSCIENCES, INC.

Effective: 2022-09-20
Filed: September 23, 2022, 7:59 PM ET

Effective September 20, 2022, the board of directors (the “Board”) of the Company appointed Kevin Danahy to serve as Chief Executive Officer of the Company and Darrin Uecker to serve as Chief Technology Officer of the Company. Mr. Danahy previously served as the Company’s Chief Commercial Officer and Mr. Uecker previously served as the Company’s Chief Executive Officer.

Role change

Darrin Uecker

Chief Technology Officer

PLSE · PULSE BIOSCIENCES, INC.

Effective: 2022-09-20
Filed: September 23, 2022, 7:59 PM ET

Effective September 20, 2022, the board of directors (the “Board”) of the Company appointed Kevin Danahy to serve as Chief Executive Officer of the Company and Darrin Uecker to serve as Chief Technology Officer of the Company. Mr. Danahy previously served as the Company’s Chief Commercial Officer and Mr. Uecker previously served as the Company’s Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Duggan was elected as Executive Chairman at PULSE BIOSCIENCES, INC..

Action: elected
Role: Executive Chairman

Exact text from the filing

Effective September 20, 2022, Mr. Duggan, who currently serves as a director and chairman of the Company’s Board, was elected Executive Chairman of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin Danahy was appointed as Chief Executive Officer at PULSE BIOSCIENCES, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Effective September 20, 2022, the board of directors (the “Board”) of the Company appointed Kevin Danahy to serve as Chief Executive Officer of the Company and Darrin Uecker to serve as Chief Technology Officer of the Company. Mr. Danahy previously served as the Company’s Chief Commercial Officer and Mr. Uecker previously served as the Company’s Chief Executive Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Darrin Uecker was appointed as Chief Technology Officer at PULSE BIOSCIENCES, INC..

Action: appointed
Role: Chief Technology Officer

Exact text from the filing

Effective September 20, 2022, the board of directors (the “Board”) of the Company appointed Kevin Danahy to serve as Chief Executive Officer of the Company and Darrin Uecker to serve as Chief Technology Officer of the Company. Mr. Danahy previously served as the Company’s Chief Commercial Officer and Mr. Uecker previously served as the Company’s Chief Executive Officer.

View on SEC.gov

PULSE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001387131-22-009977

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.